Abstract: A method of performing automatic tuning on a deep learning model includes: utilizing an instruction-based learned cost model to estimate a first type of operational performance metrics based on a tuned configuration of layer fusion and tensor tiling; utilizing statistical data gathered during a compilation process of the deep learning model to determine a second type of operational performance metrics based on the tuned configuration of layer fusion and tensor tiling; performing an auto-tuning process to obtain a plurality of optimal configurations based on the first type of operational performance metrics and the second type of operational performance metrics; and configure the deep learning model according to one of the plurality of optimal configurations.

Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: The present invention relates to the fields of microorgan-isms, feed, food and ecological restoration, in particular to a strain for degrading deoxynivalenol (DON) and the use thereof. The strain has the deposit number CCTCC No. M 2020565. The strain can grow by means of taking the toxic compound DON as a sole carbon source, and convert the DON into chemical components for itself. The reaction process is irreversible, the reaction conditions are moderate, and secondary pollu-tion cannot be caused. The strain provided in the present invention can be used for preparing a biological detoxification preparation for DON. The strain provided in the present invention can be used for degrading DON in feed and food raw materials, primary processing products, deep processing products and related processing byproducts. The strain provided in the present invention can be applied to various ecosystems such as soil or bodies of water polluted by DON to achieve the purposes of DON degradation and ecological restoration.

Abstract: Systems and methods related to “on/off” determinations regarding the performance of physical downlink control channel (PDCCH) monitoring during connected mode discontinuous reception (CDRX) on duration windows are disclosed herein. In some cases, a radio access network (RAN) predicts whether a downlink (DL) packet for a UE will arrive at a buffer of the RAN prior to an end of a CDRX on duration window of the UE, and sends a downlink control information (DCI) with a cyclic redundancy check (CRC) scrambled by a power-saving radio network temporary identifier (PS-RNTI) (DCP) for the CDRX on duration window indicating whether or not the UE should perform PDCCH monitoring during the CDRX on duration window based on the prediction. In some cases, a UE determines a current state of DL traffic and adaptively uses DCP monitoring based on the current state of the traffic. Aggregation level adaptation by the RAN is also discussed.

Abstract: Systems and methods related to “on/off” determinations regarding the performance of physical downlink control channel (PDCCH) monitoring during connected mode discontinuous reception (CDRX) on duration windows are disclosed herein. In some cases, a radio access network (RAN) predicts whether a downlink (DL) packet for a UE will arrive at a buffer of the RAN prior to an end of a CDRX on duration window of the UE, and sends a downlink control information (DCI) with a cyclic redundancy check (CRC) scrambled by a power-saving radio network temporary identifier (PS-RNTI) (DCP) for the CDRX on duration window indicating whether or not the UE should perform PDCCH monitoring during the CDRX on duration window based on the prediction. In some cases, a UE determines a current state of DL traffic and adaptively uses DCP monitoring based on the current state of the traffic. Aggregation level adaptation by the RAN is also discussed.

Abstract: The present invention relates to the technical field of medicines, and relates to a polyethylene glycol conjugated drug, a preparation method therefor and the use thereof. In particular, the present invention relates to a polyethylene glycol conjugated drug as shown in formula I or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug.

Abstract: A polyethylene glycol conjugate drug synergist, a preparation method therefor, and use thereof, specifically relating to a polyethylene glycol conjugate drug synergist as shown in formula I or a pharmaceutically acceptable salt thereof, a preparation method for the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylent glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, a composition containing the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof in preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: The present invention relates to the field of genetic engineering, particularly to a glucose oxidase mutant having improved thermal stability, gene and application thereof. The present invention provides several glucose oxidase GOD mutants with high catalytic efficiency and improved thermal stability, which breaks the barrier of low enzyme activity and poor stability and is suited well to meet the requirements of application to the fields of food, medicine, feed and textile industry, and has a very broad application prospect.

Abstract: The present invention relates to the field of genetic engineering, particularly to a glucoamylase TIGa15, gene and application thereof. Said glucoamylase comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 and has the excellent enzymic properties, which can be applied to feed, food, and medicine industries, can be industrially produce with the genetic engineering technics.

Abstract: The present invention provides use of a manganese peroxidase in the detoxification of mycotoxins, and specifically, the present invention provides five manganese peroxidases (MnP-1, MnP-2, MnP-4, MnP-5, and MnP-6), genes thereof, and uses thereof. The present invention provides five manganese peroxidases (MnP-1, MnP-2, MnP-4, MnP-5, and MnP-6) derived from lignocellulose degradation bacteria, the amino acid sequences thereof being as set forth in SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, and SEQ ID NO: 13.

Abstract: The present invention relates to the technical field of medicines, and relates to a polyethylene glycol conjugated drug, a preparation method therefor and the use thereof. In particular, the present invention relates to a polyethylene glycol conjugated drug as shown in formula I or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or the pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: The disclosure relates to the technical field of medicine, specifically to a polyethylene glycol conjugated drug, a preparation method therefor and use thereof, and relates in particular to a polyethylene glycol conjugated drug represented by formula (I) or a pharmaceutically acceptable salt thereof. The disclosure further relates to a method for preparation of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof in preparation of a medicament.

Abstract: A data backup method includes querying a first block of a first blockchain for unused transaction output information based on a first condition being met, the first block including each block of all blocks included in the first blockchain; generating transaction information according to the unused transaction output information obtained based on the querying, the transaction information indicating a transaction operation based on an account address to which the unused transaction output information belongs; recording the transaction information in a second block and releasing the second block, and recording the second block on which a consensus is reached on a second blockchain; and backing up the first blockchain into a storage system, and deleting the first blockchain. Counterpart apparatus, terminal, server, and/or non-transitory computer-readable medium are also contemplated.

Abstract: A method for processing account information in a block chain is provided. A computer device receives identity information and a transfer request, the transfer request requesting to transfer a resource in an account to a target account, the target account being generated by a certificate center. The computer device obtains owner information of the account from the certificate center according to the transfer request. The computer device compares the identity information and the owner information. The computer device transmits an authentication request to the block chain in response to determining that the identity information and the owner information are consistent, the authentication request requesting the block chain to transfer the resource in the account to the target account.

Abstract: A method for preparing formamide compounds via hydrogenation of carbon dioxide catalyzed by porous materials includes the following steps: by taking porous organometallic polymers as catalysts, reacting amine compounds with carbon dioxide and hydrogen under an air atmosphere to prepare formamide compounds. The method has the advantages of high reaction efficiency, good selectivity, mild conditions, economy, environmental protection, and simple operation. The catalysts are solid organometallic polymers with large specific surface area, strong carbon dioxide adsorption, hierarchical pore distribution, and uniformly dispersed metal centers. They are designed and synthesized as the reaction catalysts by changing the proportion of the cross-linked comonomer. The catalysts can be especially used for catalytic synthesis of fine chemical N, N-dimethylformamide (DMF) without addition of any additional solvent, alkali, or other additives, which is convenient for separation and purification of DMF.

Abstract: The present invention takes the glucose oxidase GOD from Aspergillus niger as the mutation template to obtain the glucose oxidase GOD mutants with improved catalytic efficiency and thermal stability by site directed mutagenesis. The specific activity of the mutant of the present invention is 66% higher than that of the wild type GOD; the enzyme activity of the mutant of the present invention is 13.6 times higher than that of the wild type after being treated at 70° C. for 10 min; and the enzyme activity of the mutant of the present invention is 29.4 times higher than that of the wild type after being treated at 80° C. for 2 min.

Abstract: The present invention relates to a mannanase PMan5A mutant having improved heat resistance, a gene encoding the mutant and application thereof. The mutant is obtained by a substitution of histidine with tyrosine at amino acid residue 93, phenylalanine with tyrosine at amino acid residue 94, leucine with histidine at amino acid residue 356, and/or alanine with proline at amino acid residue 389. The thermal tolerance of the single site mutation mutant H93Y, L356H and A389P are greatly improved over that of the wild-type mannanase PMan5A, and the thermal tolerance of the combination mutants shows the stack effect of the single site mutation, demonstrating the amino acids at the sites of 93, 94, 356, and 389 play an important role for the thermal stability of the mannanase of GH5 family.

Abstract: The present invention relates to the field of agriculture biotechnology, specially relates to an amylase mutant having high specific activity and thermal stability, gene and use thereof. Said amylase mutant is obtained by performing substitution of S33A/S34E/V35H, and deletion of amino acids at the sites of 178 and 179 of the wild type amylase having amino acid sequence of SEQ ID NO:1, and having improved enzymatic activity and thermal stability than the wild type amylase.